Med-tech gainers and losers for Nov. 24-26, 2025

Endpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025

Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam

PharmaVoiceCompetition is brewing between ADCs and bispecifics

Promega BlogThe Hidden Switch That Controls Lysosome Function

FierceBiotechCardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO

FierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3

CellDNA repair drives cisplatin-induced neuronal death

CellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans

CellPersistent and transient senescent cells contribute to brain-barrier development

CellContinuous modeling of primate embryogenesis from totipotency to early organogenesis

CellRNA structure programs endogenous ADAR for precise and efficient editing

FierceBiotech‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO